Moneycontrol PRO
Check Credit Score
Check Credit Score
HomeNewsBusiness

Granules gets USFDA nod for ADHD treatment drug

The approved product is bioequivalent to the reference listed drug product (RLD), Ritalin LA extended-release capsules of Novartis Pharmaceuticals Corporation.

May 27, 2019 / 10:50 AM IST
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Drug firm Granules India on Monday said its subsidiary has received approval from the US health regulator for Methylphenidate Hydrochloride extended-release capsules, used for the treatment of attention deficit hyperactivity disorder (ADHD).

The approved product is bioequivalent to the reference listed drug product (RLD), Ritalin LA extended-release capsules of Novartis Pharmaceuticals Corporation.

The US Food and Drug Administration (USFDA) has approved the abbreviated new drug application (ANDA) filed by Granules Pharmaceuticals, a wholly-owned foreign subsidiary of Granules India, for Methylphenidate Hydrochloride extended-release capsules in the strengths of 10 mg, 20 mg, 30 mg, 40 mg and 60 mg, Granules said in a BSE filing.

Granules India said, till date, Granules Pharmaceuticals had submitted total 19 ANDAs and the current approval is the third ANDA approval for the entity. Go-ahead for the balance 16 ANDAs are awaited.

Shares of Granules India were trading 1.54 per cent higher at Rs 112.80 apiece on BSE.

PTI
first published: May 27, 2019 10:40 am

Discover the latest business news, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347